Hospodárske výsledky spoločnosti Kazia Therapeutics
Aká je hodnota metriky Hospodárske výsledky spoločnosti Kazia Therapeutics?
Hodnota metriky Hospodárske výsledky spoločnosti Kazia Therapeutics Limited je N/A
Aká je definícia metriky Hospodárske výsledky?
Dátum zverejnenia hospodárskych výsledkov (Earnings date) je dátum ďaľšieho zverejnenia finančnej správy spoločnosti.
Earnings report date is the date of an official announcement about a company's profitability for a specific time period. In the private sector, a quarterly finance report is a financial report that covers three months of the year, which is required by numbers of stock exchanges around the world to provide information to investors on the state of a company.
Čomu sa venuje spoločnosť Kazia Therapeutics?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.